All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
In this video, Jabbour discusses the impact of targeted therapies for adult patients with ALL, including tyrosine kinase inhibitors, monoclonal and conjugated antibodies, bispecific engagers, and chimeric antigen receptor (CAR) T cells. He believes targeted therapies significantly improve the outcomes of patients with high disease burden.
How should we treat a patient who has a molecular relapse after transplant?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford University, Stanford, US. We asked, How should we...
Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells
The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in China. Jianxiang Wang presented this topic at the 2nd...
Subscribe to get the best content related to ALL delivered to your inbox